NASDAQ:FENC - Fennec Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $14.00
  • Forecasted Upside: 125.08 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$6.22
▼ -0.04 (-0.64%)
1 month | 3 months | 12 months
Get New Fennec Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FENC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FENC

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$14.00
▲ +125.08% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Fennec Pharmaceuticals in the last 3 months. The average price target is $14.00, with a high forecast of $18.00 and a low forecast of $11.00. The average price target represents a 125.08% upside from the last price of $6.22.
Buy
The current consensus among 4 contributing investment analysts is to buy stock in Fennec Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/28/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/26/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/25/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/24/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/22/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/20/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/21/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/20/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/19/2021Maxim GroupInitiated CoverageBuy$12.00Low
i
3/17/2021WedbushReiterated RatingOutperformHigh
i
Rating by D. Nierengarten at Wedbush
8/12/2020WedbushLower Price TargetHold ➝ Outperform$18.00 ➝ $11.00High
i
6/23/2020WedbushReiterated RatingOutperform$18.00Low
i
6/4/2020Cantor FitzgeraldInitiated CoverageOverweight$18.00High
i
Rating by C. Duncan at Cantor Fitzgerald
5/15/2020HC WainwrightReiterated RatingBuy$17.00 ➝ $15.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
4/15/2020HC WainwrightReiterated RatingBuy$17.00High
i
Rating by Ram Selvaraju at HC Wainwright
2/18/2020HC WainwrightReiterated RatingBuy$17.00Low
i
Rating by Ram Selvaraju at HC Wainwright
2/11/2020HC WainwrightReiterated RatingBuy$17.00Low
i
Rating by Ram Selvaraju at HC Wainwright
12/2/2019HC WainwrightReiterated RatingBuy$17.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
5/28/2019HC WainwrightSet Price TargetBuy$17.00Low
i
Rating by Ram Selvaraju at HC Wainwright
5/10/2019WedbushReiterated RatingOutperform$16.00High
i
3/14/2019WedbushReiterated RatingOutperform$16.00High
i
12/21/2018HC WainwrightSet Price TargetBuy$18.00Low
i
Rating by Ram Selvaraju at HC Wainwright
12/10/2018HC WainwrightReiterated RatingBuy$18.00Low
i
Rating by Ram Selvaraju at HC Wainwright
10/11/2018The Goldman Sachs GroupInitiated CoverageBuyHigh
i
10/11/2018Dawson JamesInitiated CoverageBuyHigh
i
Rating by C. Werther at Dawson James
9/17/2018WedbushLower Price TargetOutperform$17.00 ➝ $16.00Low
i
8/14/2018HC WainwrightSet Price TargetBuy$18.00Low
i
Rating by Ram Selvaraju at HC Wainwright
8/7/2018HC WainwrightSet Price TargetBuy$18.00High
i
Rating by Ram Selvaraju at HC Wainwright
6/20/2018HC WainwrightReiterated RatingBuy$18.00Low
i
Rating by Ram Selvaraju at HC Wainwright
5/23/2018HC WainwrightReiterated RatingBuy$18.00High
i
Rating by Ram Selvaraju at HC Wainwright
4/2/2018HC WainwrightReiterated RatingBuy$18.00Low
i
Rating by Ram Selvaraju at HC Wainwright
3/22/2018HC WainwrightReiterated RatingBuy$16.00Medium
i
Rating by R. Selvaraju at HC Wainwright
3/12/2018WedbushInitiated CoverageOutperform$17.00High
i
Rating by D. Nierengarten at Wedbush
2/20/2018HC WainwrightInitiated CoverageBuy ➝ Buy$16.00Medium
i
Rating by R. Selvaraju at HC Wainwright
11/29/2017LaidlawInitiated CoverageBuy ➝ Buy$22.00High
i
(Data available from 4/21/2016 forward)
Fennec Pharmaceuticals logo
Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.
Read More

Today's Range

Now: $6.22
$5.97
$6.38

50 Day Range

MA: $6.80
$5.99
$7.70

52 Week Range

Now: $6.22
$4.80
$10.67

Volume

116,192 shs

Average Volume

100,987 shs

Market Capitalization

$161.74 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.07

Frequently Asked Questions

What sell-side analysts currently cover shares of Fennec Pharmaceuticals?

The following Wall Street sell-side analysts have issued reports on Fennec Pharmaceuticals in the last year: Cantor Fitzgerald, HC Wainwright, Maxim Group, Wedbush, and Zacks Investment Research.
View the latest analyst ratings for FENC.

What is the current price target for Fennec Pharmaceuticals?

4 Wall Street analysts have set twelve-month price targets for Fennec Pharmaceuticals in the last year. Their average twelve-month price target is $14.00, suggesting a possible upside of 125.1%. Cantor Fitzgerald has the highest price target set, predicting FENC will reach $18.00 in the next twelve months. Wedbush has the lowest price target set, forecasting a price of $11.00 for Fennec Pharmaceuticals in the next year.
View the latest price targets for FENC.

What is the current consensus analyst rating for Fennec Pharmaceuticals?

Fennec Pharmaceuticals currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe FENC will outperform the market and that investors should add to their positions of Fennec Pharmaceuticals.
View the latest ratings for FENC.

What other companies compete with Fennec Pharmaceuticals?

How do I contact Fennec Pharmaceuticals' investor relations team?

Fennec Pharmaceuticals' physical mailing address is PO BOX 13628 68 TW ALEXANDER DRIVE, DURHAM NC, 27709. The company's listed phone number is 919-636-4530. The official website for Fennec Pharmaceuticals is www.fennecpharma.com.